stoxline Quote Chart Rank Option Currency Glossary
Vir Biotechnology, Inc. (VIR)
10.36  -0.12 (-1.15%)    06-13 16:00
Open: 10.44
High: 10.44
Volume: 865,528
Pre. Close: 10.48
Low: 10.08
Market Cap: 1,410(M)
Technical analysis
2024-06-13 4:47:04 PM
Short term     
Mid term     
Targets 6-month :  13.62 1-year :  15.28
Resists First :  11.66 Second :  13.09
Pivot price 10.82
Supports First :  9.35 Second :  7.78
MAs MA(5) :  10.78 MA(20) :  10.66
MA(100) :  9.92 MA(250) :  11.42
MACD MACD :  0.3 Signal :  0.4
%K %D K(14,3) :  19.7 D(3) :  30.4
RSI RSI(14): 49
52-week High :  26.15 Low :  7.61
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ VIR ] has closed above bottom band by 32.3%. Bollinger Bands are 24.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.51 - 10.61 10.61 - 10.67
Low: 9.87 - 10 10 - 10.08
Close: 10.21 - 10.42 10.42 - 10.56
Company Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Headline News

Thu, 13 Jun 2024
Bridgeway Capital Management LLC Has $13.52 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Wed, 12 Jun 2024
Vir Biotechnology, Inc. (NASDAQ:VIR) Director Saira Ramasastry Sells 4,000 Shares - MarketBeat

Wed, 12 Jun 2024
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down to $11.23 - Defense World

Mon, 10 Jun 2024
Following a 58% decline over last year, recent gains may please Vir Biotechnology, Inc. (NASDAQ:VIR) institutional owners - Simply Wall St

Wed, 05 Jun 2024
Vir Biotechnology (VIR) PT Raised to $15 at Morgan Stanley -

Thu, 23 May 2024
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 136 (M)
Shares Float 91 (M)
Held by Insiders 11.7 (%)
Held by Institutions 76.2 (%)
Shares Short 6,210 (K)
Shares Short P.Month 5,150 (K)
Stock Financials
EPS -4.02
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 11.39
Profit Margin 0 %
Operating Margin -142.1 %
Return on Assets (ttm) -16.8 %
Return on Equity (ttm) -30.7 %
Qtrly Rev. Growth -10.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.58
EBITDA (p.s.) -4.26
Qtrly Earnings Growth 0 %
Operating Cash Flow -762 (M)
Levered Free Cash Flow -612 (M)
Stock Valuations
PE Ratio -2.59
PEG Ratio -0.5
Price to Book value 0.9
Price to Sales 17.7
Price to Cash Flow -1.85
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android